Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANAPTYSBIO, INCANAB · Entity 4640 | Director | January 06, 2026 | January 08, 2026 |
| Akebia Therapeutics, Inc.AKBA · Entity 6105 | SVP, Chief Medical Officer | April 11, 2019 | April 12, 2019 |
| Avalo Therapeutics, Inc.AVTX · Entity 4936 | Director | September 30, 2026 | October 03, 2026 |
| Celldex Therapeutics, Inc.CLDX · Entity 4208 | Director | June 25, 2026 | June 29, 2026 |
| First Tracks Biotherapeutics, Inc.TRAX · Entity 4696 | Director | June 15, 2026 | June 17, 2026 |
| Immunovant, Inc.IMVT · Entity 3632 | Chief Medical Officer | March 19, 2021 | March 31, 2021 |
| SAB Biotherapeutics, Inc.SABS · Entity 5816 | Director | January 05, 2026 | January 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANAPTYSBIO, INC
Report date January 06, 2026 · Filed January 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.91 · Expires 2036-01-05 | Direct | 5,500 |
Reported balance
After 2026-01-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-06 · Grant · Acquired 5,500 · Balance 5,500 F1: The stock option vests as to 1/12 of the total shares monthly commencing on Februray 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 4,000 |
Reported balance
After 2026-01-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-06 · Grant · Acquired 4,000 · Balance 4,000 F2: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests as to 1/12 of the total shares monthly commencing on Februray 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F2: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
F3: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Akebia Therapeutics, Inc.
Report date April 11, 2019 · Filed April 12, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 96,332 |
Reported balance
After 2019-04-11 transaction · row 1
1 source rowRow 1 · 2019-04-11 · Disposition to issuer · Disposed 4,409 · Balance 96,332 F1: The proceeds from the disposition of these shares are to be used by the reporting person to cover tax liabilities associated with previously vested restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: The proceeds from the disposition of these shares are to be used by the reporting person to cover tax liabilities associated with previously vested restricted stock units.
Avalo Therapeutics, Inc.
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.33 · Expires 2036-09-30 | Direct | 1,322 |
Reported balance
After 2026-09-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 1,322 · Balance 1,322 F2: The options were issued to the Reporting Person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Plan in lieu of Board fees. F1: The options were granted on September 30, 2026, and are 100% vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted on September 30, 2026, and are 100% vested.
F2: The options were issued to the Reporting Person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Plan in lieu of Board fees.
Celldex Therapeutics, Inc.
Report date June 25, 2026 · Filed June 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.09 · Expires 2036-06-25 | Direct | 26,000 |
Reported balance
After 2026-06-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-25 · Grant · Acquired 26,000 · Balance 26,000 F1: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.
First Tracks Biotherapeutics, Inc.
Report date June 15, 2026 · Filed June 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,194 |
Reported balance
After 2026-06-15 transaction · row 1
1 source rowRow 1 · 2026-06-15 · Exercise / conversion · Acquired 7,330 · Balance 19,194 F1: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-15 · Exercise / conversion · Disposed 6,030 · Balance 0 F1: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2: The RSUs vests as to 100% of the total RSUs on June 15, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-15 · Exercise / conversion · Disposed 1,300 · Balance 0 F1: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3: The RSUs shall vest as to 33.33% of the total shares on June 15, 2024, and thereafter vests as to 33.33% of the total RSUs on June 15, 2025; and as to 33.33% of the total RSUs on June 15, 2026, subject to the provision of services to the Company on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
F2: The RSUs vests as to 100% of the total RSUs on June 15, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F3: The RSUs shall vest as to 33.33% of the total shares on June 15, 2024, and thereafter vests as to 33.33% of the total RSUs on June 15, 2025; and as to 33.33% of the total RSUs on June 15, 2026, subject to the provision of services to the Company on each vesting date.
Immunovant, Inc.
Report date March 19, 2021 · Filed March 31, 2021 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 129,365 |
Last balance in matching sequence
After 2021-03-19 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2021-03-19 · Grant · Acquired 97,600 · Balance 117,600 F1: Represents the number of shares underlying restricted stock units awards ("RSUs"). F2: The RSUs vest over four years, with 25% of the RSUs vesting on March 19, 2022 and the remainder of the RSUs vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Row 2 · 2021-03-19 · Grant · Acquired 11,765 · Balance 129,365 F1: Represents the number of shares underlying restricted stock units awards ("RSUs"). F3: The original Form 4, filed on March 23, 2021, is being amended by this Form 4 amendment solely to correct an administrative error related to the disclosure of the vesting schedule for 11,765 RSUs. These RSUs vest in their entirety six months after the date of grant on September 19, 2021, subject to the Reporting Person providing continuous service to the Issuer as of such date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2031-03-19 | Direct | 342,300 |
Reported balance
After 2021-03-19 transaction · row 3
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 3 · 2021-03-19 · Grant · Acquired 342,300 · Balance 342,300 F4: Shares underlying the options vest over four years, with 25% of the shares underlying the options vesting on March 19, 2022 and the remainder of the shares underlying the options vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares underlying restricted stock units awards ("RSUs").
F2: The RSUs vest over four years, with 25% of the RSUs vesting on March 19, 2022 and the remainder of the RSUs vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.
F3: The original Form 4, filed on March 23, 2021, is being amended by this Form 4 amendment solely to correct an administrative error related to the disclosure of the vesting schedule for 11,765 RSUs. These RSUs vest in their entirety six months after the date of grant on September 19, 2021, subject to the Reporting Person providing continuous service to the Issuer as of such date.
F4: Shares underlying the options vest over four years, with 25% of the shares underlying the options vesting on March 19, 2022 and the remainder of the shares underlying the options vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.
SAB Biotherapeutics, Inc.
Report date January 05, 2026 · Filed January 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.74 · Expires 2036-01-05 | Direct | 240,000 |
Reported balance
After 2026-01-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-05 · Grant · Acquired 240,000 · Balance 240,000 F1: Represents the inaugural grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in three equal annual installments on January 5, 2027, January 5, 2028 and January 5, 2029. F2: This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the inaugural grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in three equal annual installments on January 5, 2027, January 5, 2028 and January 5, 2029.
F2: This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ChemoCentryx, Inc.
Report date October 20, 2022 · Filed October 24, 2022
Section 16 reporting ended · disclosed 2022-10-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-10-20 transaction · row 1
1 source rowRow 1 · 2022-10-20 · Disposition to issuer · Disposed 35,863 · Balance 0 F1: Reflects the disposition of securities pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 3, 2022, among Amgen Inc. ("Parent"), Carnation Merger Sub, Inc. ("Merger Sub") and ChemoCentryx, Inc. (the "Company"), pursuant to which, on October 20, 2022, Merger Sub merged with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Company (collectively, the "Shares," and each such share, a "Share") (other than any such Shares (i) held by the Company as treasury stock or owned by Parent or Merger Sub, (ii) held by any subsidiary of the Company or Parent (other than Merger Sub) or (iii) as to which appraisal rights have been properly exercised, F2: (Continued from Footnote 1) and not withdrawn, in accordance with the Delaware General Corporation Law) was thereupon canceled and converted into the right to receive $52.00 in cash, without interest (the "Merger Consideration"). As a result of the Merger, the Reporting Person no longer beneficially owns, directly or indirectly, any Shares. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $29.83 | Direct | 0 |
Reported balance
After 2022-10-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-10-20 · Disposition to issuer · Disposed 307 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $29.83 | Direct | 0 |
Reported balance
After 2022-10-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-10-20 · Disposition to issuer · Disposed 14,393 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $19.00 | Direct | 0 |
Reported balance
After 2022-10-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-10-20 · Disposition to issuer · Disposed 21,052 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $19.00 | Direct | 0 |
Reported balance
After 2022-10-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-10-20 · Disposition to issuer · Disposed 23,948 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $10.06 | Direct | 0 |
Reported balance
After 2022-10-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-10-20 · Disposition to issuer · Disposed 4,504 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $11.60 | Direct | 0 |
Reported balance
After 2022-10-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-10-20 · Disposition to issuer · Disposed 12,287 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-10-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-10-20 · Disposition to issuer · Disposed 11,600 · Balance 0 F4: At the Effective Time, each restricted stock unit of the Company held by the Reporting Person that was outstanding immediately prior to the Effective Time and that was (A) granted prior to August 3, 2022 or granted after August 3, 2022 and specified in the disclosure schedules delivered by the Company to Parent in connection with the Merger Agreement and/or (B) granted to a non-employee member of the Board became fully vested and was cancelled and converted into the right to receive an amount in cash, less applicable withholding taxes and without interest, equal to (x) the total number of Shares underlying such restricted stock unit multiplied by (y) $52.00. The restricted stock units did not have an expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of securities pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 3, 2022, among Amgen Inc. ("Parent"), Carnation Merger Sub, Inc. ("Merger Sub") and ChemoCentryx, Inc. (the "Company"), pursuant to which, on October 20, 2022, Merger Sub merged with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Company (collectively, the "Shares," and each such share, a "Share") (other than any such Shares (i) held by the Company as treasury stock or owned by Parent or Merger Sub, (ii) held by any subsidiary of the Company or Parent (other than Merger Sub) or (iii) as to which appraisal rights have been properly exercised,
F2: (Continued from Footnote 1) and not withdrawn, in accordance with the Delaware General Corporation Law) was thereupon canceled and converted into the right to receive $52.00 in cash, without interest (the "Merger Consideration"). As a result of the Merger, the Reporting Person no longer beneficially owns, directly or indirectly, any Shares.
F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option.
F4: At the Effective Time, each restricted stock unit of the Company held by the Reporting Person that was outstanding immediately prior to the Effective Time and that was (A) granted prior to August 3, 2022 or granted after August 3, 2022 and specified in the disclosure schedules delivered by the Company to Parent in connection with the Merger Agreement and/or (B) granted to a non-employee member of the Board became fully vested and was cancelled and converted into the right to receive an amount in cash, less applicable withholding taxes and without interest, equal to (x) the total number of Shares underlying such restricted stock unit multiplied by (y) $52.00. The restricted stock units did not have an expiration date.
Provention Bio, Inc.
Report date April 27, 2023 · Filed April 27, 2023
Section 16 reporting ended · disclosed 2023-04-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $9.67 | Direct | 0 |
Reported balance
After 2023-04-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-04-27 · Disposition to issuer · Disposed 66,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full.
F2: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2026 Filed Oct 3, 2026 00:15 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 1,322 | $12.29 Strike: $15.33 | $16,247.38 |
DisclosureSEC source: 0001707797-26-000017 · form4-10022026_041020.xml · derivative · entry 1 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,322 Underlying: Common Stock · 1,322 shares Expires 2036-09-30 F2 · price: The options were issued to the Reporting Person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Plan in lieu of Board fees. F1 · derivative.exercise_date: The options were granted on September 30, 2026, and are 100% vested. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 20:05 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 1,080 | $15.04 Strike: $18.48 | $16,243.20 |
DisclosureSEC source: 0001707797-26-000014 · form4-07022026_040717.xml · derivative · entry 1 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,080 Underlying: Common Stock · 1,080 shares Expires 2036-06-30 F1 · derivative.exercise_date: The options were granted on June 30, 2026, and are 100% vested. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 20:11 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 26,000 | $0.00 Strike: $34.09 | $0.00 |
DisclosureSEC source: 0001707797-26-000012 · form4-06292026_080641.xml · derivative · entry 1 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2036-06-25 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | Exercise / conversionRestricted Stock Unit · Derivative | 1,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001707797-26-000010 · form4-06172026_040621.xml · derivative · entry 3 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs shall vest as to 33.33% of the total shares on June 15, 2024, and thereafter vests as to 33.33% of the total RSUs on June 15, 2025; and as to 33.33% of the total RSUs on June 15, 2026, subject to the provision of services to the Company on each vesting date. F3 · derivative.expiration_date: The RSUs shall vest as to 33.33% of the total shares on June 15, 2024, and thereafter vests as to 33.33% of the total RSUs on June 15, 2025; and as to 33.33% of the total RSUs on June 15, 2026, subject to the provision of services to the Company on each vesting date. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | Exercise / conversionRestricted Stock Unit · Derivative | 6,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001707797-26-000010 · form4-06172026_040621.xml · derivative · entry 2 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,030 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on June 15, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F2 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on June 15, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | Exercise / conversionCommon Stock | 7,330 | $0.00 | $0.00 |
DisclosureSEC source: 0001707797-26-000010 · form4-06172026_040621.xml · nonDerivative · entry 1 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,194 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| June 02, 2026 Filed Jun 4, 2026 20:10 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 20,100 | $0.00 Strike: $13.96 | $0.00 |
DisclosureSEC source: 0001707797-26-000008 · form4-06042026_040601.xml · derivative · entry 1 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,100 Underlying: Common Stock · 20,100 shares Expires 2036-06-02 F1 · derivative.exercise_date: The stock option vests 100% on the first anniversary of the date of grant, subject to the director's continued service on such vesting date. Read SEC document |
| May 12, 2026 Filed May 14, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantStock Option (right to buy) · Derivative | 42,000 | $0.00 Strike: $17.81 | $0.00 |
DisclosureSEC source: 0001707797-26-000006 · form4-05142026_040511.xml · derivative · entry 2 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires 2036-05-11 F3 · derivative.exercise_date: The stock option vests as to 1/12 of the total shares monthly commencing on June 12, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F4 · balance_after: In addition to the options to purchase a total of 42,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 57,135 shares of common stock, which options vest according to their terms. Read SEC document |
| May 12, 2026 Filed May 14, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantRestricted Stock Unit · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001707797-26-000006 · form4-05142026_040511.xml · derivative · entry 1 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F2 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| May 12, 2026 Filed Jun 12, 2026 20:09 UTC Amendment | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantStock Option (right to buy) · Derivative | 7,000 | $0.00 Strike: $17.81 | $0.00 |
DisclosureSEC source: 0001707797-26-000009 · form4a-06122026_080656.xml · derivative · entry 2 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2036-05-11 F3 · derivative.exercise_date: The stock option vests as to 1/12 of the total shares monthly commencing on June 12, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| May 12, 2026 Filed Jun 12, 2026 20:09 UTC Amendment | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantRestricted Stock Unit · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001707797-26-000009 · form4a-06122026_080656.xml · derivative · entry 1 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F2 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantRestricted Stock Unit · Derivative | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001707797-26-000005 · form4-04222026_040409.xml · derivative · entry 9 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F6 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation Agreement, each outstanding RSU with respect to AnaptysBio shares of common stock was adjusted so that such RSU became an RSU with respect to First Tracks shares of common stock and an RSU with respect to AnaptysBio's shares of common stock. As a result, the Reporting Person acquired RSU s with respect to First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. F9 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F9 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantRestricted Stock Unit · Derivative | 6,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001707797-26-000005 · form4-04222026_040409.xml · derivative · entry 8 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,030 Underlying: Common Stock · 6,030 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F6 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation Agreement, each outstanding RSU with respect to AnaptysBio shares of common stock was adjusted so that such RSU became an RSU with respect to First Tracks shares of common stock and an RSU with respect to AnaptysBio's shares of common stock. As a result, the Reporting Person acquired RSU s with respect to First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. F8 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2026 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F8 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2026 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantRestricted Stock Unit · Derivative | 1,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001707797-26-000005 · form4-04222026_040409.xml · derivative · entry 7 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,300 Underlying: Common Stock · 1,300 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F6 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation Agreement, each outstanding RSU with respect to AnaptysBio shares of common stock was adjusted so that such RSU became an RSU with respect to First Tracks shares of common stock and an RSU with respect to AnaptysBio's shares of common stock. As a result, the Reporting Person acquired RSU s with respect to First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. F7 · derivative.exercise_date: The RSUs shall vest as to 33.33% of the total shares on June 15, 2024, and thereafter vests as to 33.33% of the total RSUs on June 15, 2025; and as to 33.33% of the total RSUs on June 15, 2026, subject to the provision of services to the Company on each vesting date. F7 · derivative.expiration_date: The RSUs shall vest as to 33.33% of the total shares on June 15, 2024, and thereafter vests as to 33.33% of the total RSUs on June 15, 2025; and as to 33.33% of the total RSUs on June 15, 2026, subject to the provision of services to the Company on each vesting date. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantStock Option (right to buy) · Derivative | 5,500 | $0.00 Strike: $11.75 | $0.00 |
DisclosureSEC source: 0001707797-26-000005 · form4-04222026_040409.xml · derivative · entry 6 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 5,500 shares Expires 2036-01-06 F2 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. F4 · derivative.exercise_date: The stock option vests as to 1/12 of the total shares monthly commencing on February 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantStock Option (right to buy) · Derivative | 16,510 | $0.00 Strike: $3.97 | $0.00 |
DisclosureSEC source: 0001707797-26-000005 · form4-04222026_040409.xml · derivative · entry 5 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,510 Underlying: Common Stock · 16,510 shares Expires 2035-01-06 F2 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. F3 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantStock Option (right to buy) · Derivative | 16,510 | $0.00 Strike: $5.67 | $0.00 |
DisclosureSEC source: 0001707797-26-000005 · form4-04222026_040409.xml · derivative · entry 4 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,510 Underlying: Common Stock · 16,510 shares Expires 2034-01-02 F2 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. F3 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantStock Option (right to buy) · Derivative | 8,015 | $0.00 Strike: $5.91 | $0.00 |
DisclosureSEC source: 0001707797-26-000005 · form4-04222026_040409.xml · derivative · entry 3 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,015 Underlying: Common Stock · 8,015 shares Expires 2033-04-02 F2 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. F3 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantStock Option (right to buy) · Derivative | 10,600 | $0.00 Strike: $5.91 | $0.00 |
DisclosureSEC source: 0001707797-26-000005 · form4-04222026_040409.xml · derivative · entry 2 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,600 Underlying: Common Stock · 10,600 shares Expires 2033-04-02 F2 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. F3 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| March 31, 2026 Filed Apr 1, 2026 20:05 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 1,339 | $12.13 Strike: $14.93 | $16,242.07 |
DisclosureSEC source: 0001707797-26-000003 · form4-04012026_040410.xml · derivative · entry 1 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,339 Underlying: Common Stock · 1,339 shares Expires 2036-03-31 F1 · derivative.exercise_date: The options were granted on March 31, 2026, and are 100% vested. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 21:06 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantRestricted Stock Unit · Derivative | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001707797-26-000001 · form4-01082026_090134.xml · derivative · entry 2 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 21:06 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 5,500 | $0.00 Strike: $43.91 | $0.00 |
DisclosureSEC source: 0001707797-26-000001 · form4-01082026_090134.xml · derivative · entry 1 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 5,500 shares Expires 2036-01-05 F1 · derivative.exercise_date: The stock option vests as to 1/12 of the total shares monthly commencing on Februray 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 21:41 UTC | SAB Biotherapeutics, Inc. SABS · Entity 5816 | GrantStock Option (right to buy) · Derivative | 240,000 | $0.00 Strike: $3.74 | $0.00 |
DisclosureSEC source: 0001193125-26-006435 · ownership.xml · derivative · entry 1 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,000 Underlying: Common Stock · 240,000 shares Expires 2036-01-05 F1 · security: Represents the inaugural grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in three equal annual installments on January 5, 2027, January 5, 2028 and January 5, 2029. F2 · security: This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended. F1 · derivative.exercise_date: Represents the inaugural grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in three equal annual installments on January 5, 2027, January 5, 2028 and January 5, 2029. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 21:05 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 1,043 | $14.74 Strike: $18.16 | $15,373.82 |
DisclosureSEC source: 0001470831-26-000006 · form4.xml · derivative · entry 1 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,043 Underlying: Common Stock · 1,043 shares Expires 2035-12-31 F1 · derivative.exercise_date: The options were granted on December 31, 2025, and are 100% vested. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 20:11 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 1,572 | $0.00 Strike: $12.71 | $0.00 |
DisclosureSEC source: 0001707797-25-000006 · primary_doc.xml · derivative · entry 1 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,572 Underlying: Common Stock · 1,572 shares Expires 2035-09-30 F1 · derivative.exercise_date: The options were granted on September 30, 2025, and are 100% vested. Read SEC document |
| June 17, 2025 Filed Jun 18, 2025 20:08 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 40,200 | $0.00 Strike: $4.47 | $0.00 |
DisclosureSEC source: 0001578563-25-000318 · primary_doc.xml · derivative · entry 1 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,200 Underlying: Common Stock · 40,200 shares Expires 2035-06-17 F1 · derivative.exercise_date: The stock option vests in three substantially equal installments on the first, second and third anniversary of the date of grant, subject to the Eligible Director's continued service on each such vesting date. Read SEC document |
| June 15, 2025 Filed Jun 17, 2025 22:33 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionRestricted Stock Unit · Derivative | 6,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-017592 · form4-06172025_100645.xml · derivative · entry 3 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,030 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2025 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2025 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| June 15, 2025 Filed Jun 17, 2025 22:33 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionRestricted Stock Unit · Derivative | 1,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-017592 · form4-06172025_100645.xml · derivative · entry 2 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,300 Underlying: Common Stock · 1,300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: The RSUs shall vest as to 1/3 of the total shares on June 15, 2024, and thereafter vests as to 1/3 of the total RSUs on June 15, 2025; and as to 1/3 of the total RSUs on June 15, 2026, subject to the provision of services to the Company on each vesting date. F2 · derivative.expiration_date: The RSUs shall vest as to 1/3 of the total shares on June 15, 2024, and thereafter vests as to 1/3 of the total RSUs on June 15, 2025; and as to 1/3 of the total RSUs on June 15, 2026, subject to the provision of services to the Company on each vesting date. Read SEC document |
| June 15, 2025 Filed Jun 17, 2025 22:33 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 7,330 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-017592 · form4-06172025_100645.xml · nonDerivative · entry 1 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,864 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:10 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $19.53 | $0.00 |
DisclosureSEC source: 0001415889-25-016225 · form4-06092025_080641.xml · derivative · entry 1 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2035-06-05 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| January 07, 2025 Filed Jan 7, 2025 22:30 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantRestricted Stock Unit · Derivative | 6,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-001040 · form4-01072025_100153.xml · derivative · entry 2 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,030 Underlying: Common Stock · 6,030 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2026 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2026 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 07, 2025 Filed Jan 7, 2025 22:30 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 16,510 | $0.00 Strike: $14.83 | $0.00 |
DisclosureSEC source: 0001415889-25-001040 · form4-01072025_100153.xml · derivative · entry 1 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,510 Underlying: Common Stock · 16,510 shares Expires 2035-01-06 F1 · derivative.exercise_date: The stock option vests as to 1/12 of the total shares monthly commencing on Februray 7, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| June 15, 2024 Filed Jun 19, 2024 00:14 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionRestricted Stock Unit · Derivative | 1,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-017506 · form4-06192024_120600.xml · derivative · entry 3 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs shall vest as to 1/3 of the total shares on June 15, 2024, and thereafter vests as to 1/3 of the total RSUs on June 15, 2025; and as to 1/3 of the total RSUs on June 15, 2026, subject to the provision of services to the Company on each vesting date. F3 · derivative.expiration_date: The RSUs shall vest as to 1/3 of the total shares on June 15, 2024, and thereafter vests as to 1/3 of the total RSUs on June 15, 2025; and as to 1/3 of the total RSUs on June 15, 2026, subject to the provision of services to the Company on each vesting date. Read SEC document |
| June 15, 2024 Filed Jun 19, 2024 00:14 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionRestricted Stock Unit · Derivative | 3,234 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-017506 · form4-06192024_120600.xml · derivative · entry 2 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,234 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2024 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F2 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2024 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| June 15, 2024 Filed Jun 19, 2024 00:14 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 4,534 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-017506 · form4-06192024_120600.xml · nonDerivative · entry 1 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,534 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 20:11 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $36.43 | $0.00 |
DisclosureSEC source: 0001415889-24-017158 · form4-06172024_080640.xml · derivative · entry 1 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2034-06-13 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 22:01 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantRestricted Stock Unit · Derivative | 6,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-001053 · doc4.xml · derivative · entry 2 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,030 Underlying: Common Stock · 6,030 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2025 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2025 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 22:01 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 16,510 | $0.00 Strike: $21.19 | $0.00 |
DisclosureSEC source: 0001209191-24-001053 · doc4.xml · derivative · entry 1 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,510 Underlying: Common Stock · 16,510 shares Expires 2034-01-02 F1 · derivative.exercise_date: The stock option vests as to 1/12 of the total shares monthly commencing on Februray 3, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 27, 2023 Filed Apr 27, 2023 18:03 UTC | Provention Bio, Inc. PRVB · Entity 12101 | Disposition to issuerOption to Purchase Common Stock · Derivative | 66,000 | Not disclosed Strike: $9.67 | Not disclosed |
DisclosureSEC source: 0001493152-23-013912 · ownership.xml · derivative · entry 1 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 66,000 shares Expires not disclosed F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2 · price: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. F1 · derivative.exercise_date: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2 · derivative.exercise_date: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. F1 · derivative.expiration_date: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2 · derivative.expiration_date: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. Read SEC document |
| April 03, 2023 Filed Apr 6, 2023 21:05 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantRestricted Stock Unit · Derivative | 3,234 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023604 · doc4.xml · derivative · entry 4 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,234 Underlying: Common Stock · 3,234 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F5 · derivative.exercise_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2024 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F5 · derivative.expiration_date: The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2024 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 03, 2023 Filed Apr 6, 2023 21:05 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantRestricted Stock Unit · Derivative | 3,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023604 · doc4.xml · derivative · entry 3 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,900 Underlying: Common Stock · 3,900 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: The RSUs shall vest as to 1/3 of the total shares on June 15, 2024, and thereafter vests as to 1/3 of the total RSUs on June 15, 2025; and as to 1/3 of the total RSUs on June 15, 2026, subject to the provision of services to the Company on each vesting date. F4 · derivative.expiration_date: The RSUs shall vest as to 1/3 of the total shares on June 15, 2024, and thereafter vests as to 1/3 of the total RSUs on June 15, 2025; and as to 1/3 of the total RSUs on June 15, 2026, subject to the provision of services to the Company on each vesting date. Read SEC document |
| April 03, 2023 Filed Apr 6, 2023 21:05 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 8,015 | $0.00 Strike: $22.09 | $0.00 |
DisclosureSEC source: 0001209191-23-023604 · doc4.xml · derivative · entry 2 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,015 Underlying: Common Stock · 8,015 shares Expires 2033-04-02 F2 · derivative.exercise_date: The stock option vests as of 1/9 of the total shares monthly beginning on May 6, 2023 and each month thereafter until fully vested on January 6, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 03, 2023 Filed Apr 6, 2023 21:05 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 10,600 | $0.00 Strike: $22.09 | $0.00 |
DisclosureSEC source: 0001209191-23-023604 · doc4.xml · derivative · entry 1 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,600 Underlying: Common Stock · 10,600 shares Expires 2033-04-02 F1 · derivative.exercise_date: The stock option vests as of 1/36 of the total shares monthly beginning on May 6, 2023 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:30 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 17,100 | $0.00 Strike: $42.34 | $0.00 |
DisclosureSEC source: 0001493152-23-005663 · ownership.xml · derivative · entry 1 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,100 Underlying: Common Stock · 17,100 shares Expires 2033-02-16 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: One third vests on the first, second and third anniversaries of the date of grant. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 16:31 UTC | Provention Bio, Inc. PRVB · Entity 12101 | GrantStock Option (right to buy) · Derivative | 66,000 | $0.00 Strike: $9.67 | $0.00 |
DisclosureSEC source: 0001493152-23-000620 · ownership.xml · derivative · entry 1 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,000 Underlying: Common Stock, par value $0.0001 · 66,000 shares Expires 2033-01-03 F2 · price: The stock options were granted pursuant to the Provention Bio, Inc. 2017 Equity Incentive Plan. F1 · derivative.exercise_date: On January 3, 2023, the Reporting Person was granted a stock option for 66,000 shares of Common Stock which vests in equal installments every six months over a four-year period. Read SEC document |
| October 20, 2022 Filed Oct 24, 2022 19:13 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Disposition to issuerRestricted Stock Unit · Derivative | 11,600 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-034089 · doc4.xml · derivative · entry 8 Jain Rita · CIK 0001707797 · Director · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,600 shares Expires not disclosed F4 · derivative.exercise_price: At the Effective Time, each restricted stock unit of the Company held by the Reporting Person that was outstanding immediately prior to the Effective Time and that was (A) granted prior to August 3, 2022 or granted after August 3, 2022 and specified in the disclosure schedules delivered by the Company to Parent in connection with the Merger Agreement and/or (B) granted to a non-employee member of the Board became fully vested and was cancelled and converted into the right to receive an amount in cash, less applicable withholding taxes and without interest, equal to (x) the total number of Shares underlying such restricted stock unit multiplied by (y) $52.00. The restricted stock units did not have an expiration date. F4 · price: At the Effective Time, each restricted stock unit of the Company held by the Reporting Person that was outstanding immediately prior to the Effective Time and that was (A) granted prior to August 3, 2022 or granted after August 3, 2022 and specified in the disclosure schedules delivered by the Company to Parent in connection with the Merger Agreement and/or (B) granted to a non-employee member of the Board became fully vested and was cancelled and converted into the right to receive an amount in cash, less applicable withholding taxes and without interest, equal to (x) the total number of Shares underlying such restricted stock unit multiplied by (y) $52.00. The restricted stock units did not have an expiration date. F4 · derivative.exercise_date: At the Effective Time, each restricted stock unit of the Company held by the Reporting Person that was outstanding immediately prior to the Effective Time and that was (A) granted prior to August 3, 2022 or granted after August 3, 2022 and specified in the disclosure schedules delivered by the Company to Parent in connection with the Merger Agreement and/or (B) granted to a non-employee member of the Board became fully vested and was cancelled and converted into the right to receive an amount in cash, less applicable withholding taxes and without interest, equal to (x) the total number of Shares underlying such restricted stock unit multiplied by (y) $52.00. The restricted stock units did not have an expiration date. F4 · derivative.expiration_date: At the Effective Time, each restricted stock unit of the Company held by the Reporting Person that was outstanding immediately prior to the Effective Time and that was (A) granted prior to August 3, 2022 or granted after August 3, 2022 and specified in the disclosure schedules delivered by the Company to Parent in connection with the Merger Agreement and/or (B) granted to a non-employee member of the Board became fully vested and was cancelled and converted into the right to receive an amount in cash, less applicable withholding taxes and without interest, equal to (x) the total number of Shares underlying such restricted stock unit multiplied by (y) $52.00. The restricted stock units did not have an expiration date. Read SEC document |
| October 20, 2022 Filed Oct 24, 2022 19:13 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Disposition to issuerStock Option · Derivative | 12,287 | Not disclosed Strike: $11.60 | Not disclosed |
DisclosureSEC source: 0000899243-22-034089 · doc4.xml · derivative · entry 7 Jain Rita · CIK 0001707797 · Director · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,287 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. Read SEC document |
| October 20, 2022 Filed Oct 24, 2022 19:13 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Disposition to issuerStock Option · Derivative | 4,504 | Not disclosed Strike: $10.06 | Not disclosed |
DisclosureSEC source: 0000899243-22-034089 · doc4.xml · derivative · entry 6 Jain Rita · CIK 0001707797 · Director · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,504 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. Read SEC document |
| October 20, 2022 Filed Oct 24, 2022 19:13 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Disposition to issuerStock Option · Derivative | 23,948 | Not disclosed Strike: $19.00 | Not disclosed |
DisclosureSEC source: 0000899243-22-034089 · doc4.xml · derivative · entry 5 Jain Rita · CIK 0001707797 · Director · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,948 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. Read SEC document |
| October 20, 2022 Filed Oct 24, 2022 19:13 UTC | ChemoCentryx, Inc. CCXI · Entity 122928 | Disposition to issuerStock Option · Derivative | 21,052 | Not disclosed Strike: $19.00 | Not disclosed |
DisclosureSEC source: 0000899243-22-034089 · doc4.xml · derivative · entry 4 Jain Rita · CIK 0001707797 · Director · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,052 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.